Just about every industry is looking at artificial intelligence more closely right now, but the tech could become truly life-changing in health care, according to Chicago biotech executive Meesha Dogan.
Dogan is co-founder and CEO of Cardio Diagnostics Holdings Inc., which is using AI to reimagine the possibilities for detecting, treating, managing and preventing different types of cardiovascular disease.
Today, the Chicago-based AI-powered precision cardiovascular medicine company (Nasdaq: CDIO) has launched PrecisionCHD, a new blood test for the early detection of coronary heart disease. It is the second clinical test built using Cardio Diagnostics' proprietary AI-driven Integrated Epigenetic-Genetic Engine.
Dogan said that about 80% of cardiovascular events like heart attacks can be prevented, and that it's time to reimagine the way we think about caring for and preventing heart disease.
"It remains the No. 1 killer for a reason," she said.
'A technology like no other'
Dogan described PrecisionCHD as a simple blood test that could be a "game-changer" for early detection of coronary heart disease.
She said she knows how timely what her company is building is in the era of high-performance AI computing and high-throughput epigenetics.
"We have known science of genetics and epigenetics works and has been true for many decades. What we're seeing is now we have a technology that we can layer that makes the science that much more powerful," she said.
Cardio Diagnostics is also working on other tests for stroke, heart failure, diabetes and more.
Dogan said that even just a few years ago, the word "AI" was almost taboo in health care, but the industry and business world in general have come a long way in how it thinks about AI, its possibilities and power.
"There's no reason why we should be talking about better health care and precision medicine without AI being part of that conversation," she said. "We realized that's where we needed to be when trying to change health care."
Cardio Diagnostics' latest product comes as the capabilities of ChatGPT and other AI advances have thrust the technology "into the limelight" now more so than ever, she said.
"Now we get to leverage that same powerful technology and couple that to molecular data and do it at scale using AI," Dogan said. "For us, it's an opportunity to build a technology like no other. There isn't another AI-driven clinical test for coronary disease out there."
